XXXX receptor blockade improves left ventricular remodeling and @entity2224 threshold in experimental @entity712 .

@entity62944 @entity3372 @entity712 @entity1369 @entity82 @entity944 @entity384 @entity2224 @entity35 @entity583 @entity1063 @entity1482 @entity11474
OBJECTIVES: To investigate the effects of @entity1369 receptor blockade in @entity712 . METHODS: Eighty-seven @entity35 with moderate @entity583 were randomized to receive either no drug or @entity62944 , the active metabolite of @entity1482 , 20 mg/kg/day, or @entity3372 , 1 mg/kg/day, or a combination of the two drugs. Treatment was initiated 1 month after coronary ligation and lasted 4 weeks. Echocardiography was performed at baseline and after 4 weeks. LV catheterization, isolated heart studies, morphometric histology, myocardial @entity1063 and @entity11474 mRNA were assessed at the end of the treatment period. RESULTS: Infarct sizes were 33+/-3, 32+/-3, 34+/-3, and 34+/-4% in the placebo, @entity62944 , @entity3372 , and combination groups, respectively. @entity62944 attenuated LV remodeling, improved LV systolic and diastolic function, and markedly reduced interstitial and perivascular @entity82 . These effects were increased by concomitant @entity3372 therapy. Moreover, myocardial @entity1063 content was decreased while @entity2224 threshold significantly augmented by @entity62944 . @entity11474 levels remained unchanged. CONCLUSIONS: @entity62944 attenuated @entity384 and interstitial remodeling, and improved LV filling dynamics and systolic function in the @entity35 model of @entity712 . Addition of @entity3372 conferred further cardioprotection. @entity62944 also reduced myocardial @entity1063 content and @entity2224 threshold. The data provide a potential explanation for the decreased @entity944 observed in the RALES study. The mechanisms of action of @entity1369 inhibition are still poorly understood, despite its proven efficacy in @entity712 . @entity35 with @entity712 were randomized to receive for 1 month either no drug or @entity62944 , or @entity3372 , or a combination of @entity62944 and @entity3372 . @entity62944 treatment was associated with a significant attenuation of @entity384 , better LV diastolic and systolic dynamics, and a marked reduction of reactive @entity82 . These effects were enhanced by concomitant @entity3372 therapy. Moreover, @entity62944 @entity2224 threshold and reduced myocardial @entity1063 content. The data may explain the reduced mortality demonstrated by the RALES.
